UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 62 filers reported holding UROGEN PHARMA LTD in Q3 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,191 | +14.8% | 870,194 | -15.1% | 0.24% | -8.4% |
| Q2 2023 | $10,615 | +12.0% | 1,025,567 | -0.0% | 0.26% | +35.1% |
| Q1 2023 | $9,479 | +4.2% | 1,025,868 | +0.0% | 0.19% | -3.0% |
| Q4 2022 | $9,097 | -99.9% | 1,025,560 | -0.0% | 0.20% | -4.3% |
| Q3 2022 | $8,533,000 | +1.6% | 1,025,583 | -0.0% | 0.21% | +18.1% |
| Q2 2022 | $8,400,000 | -6.0% | 1,025,611 | -0.0% | 0.18% | +21.2% |
| Q1 2022 | $8,933,000 | -8.4% | 1,025,633 | -0.0% | 0.15% | -20.7% |
| Q4 2021 | $9,754,000 | +8931.5% | 1,025,675 | +34089.2% | 0.18% | +2966.7% |
| Q2 2019 | $108,000 | +45.9% | 3,000 | +50.0% | 0.01% | +50.0% |
| Q1 2019 | $74,000 | +72.1% | 2,000 | +100.0% | 0.00% | +33.3% |
| Q4 2018 | $43,000 | -65.0% | 1,000 | -61.5% | 0.00% | -50.0% |
| Q3 2018 | $123,000 | -4.7% | 2,600 | 0.0% | 0.01% | -14.3% |
| Q2 2018 | $129,000 | – | 2,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |